**Core Concept**
Polycythemia vera (PV) is a myeloproliferative disorder characterized by the excessive production of red blood cells, white blood cells, and platelets. The essential World Health Organization (WHO) criteria for diagnosing PV involve specific molecular and clinical features.

**Why the Correct Answer is Right**
The WHO criteria for PV include the presence of the JAK2 V617F mutation, a gain-of-function mutation in the JAK2 gene that leads to the constitutive activation of the JAK-STAT signaling pathway, resulting in the uncontrolled proliferation of hematopoietic cells. This mutation is found in approximately 95% of PV patients. Other mutations, such as CALR and MPL, can also be present in a subset of patients.

**Why Each Wrong Option is Incorrect**
**Option B:** Low levels of erythropoietin levels are not a specific criterion for PV. While erythropoietin levels may be low or normal in PV, this is not a diagnostic feature.
**Option C:** Thrombocytosis is a common finding in PV, but it is not an essential criterion for diagnosis. Other myeloproliferative disorders, such as essential thrombocythemia, can also present with thrombocytosis.
**Option D:** Increased mean corpuscular volume (MCV) is not a specific criterion for PV. While some PV patients may have an increased MCV, this finding is not distinctive enough to be considered an essential diagnostic feature.

**Clinical Pearl / High-Yield Fact**
The JAK2 V617F mutation is a sensitive but not specific marker for PV. It can also be found in other myeloproliferative disorders, such as essential thrombocythemia and primary myelofibrosis. A diagnosis of PV requires a combination of clinical, laboratory, and molecular findings.

✓ Correct Answer: A. Tyrosine kinase JAK2 V617F and other mutations